vs
Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and SNDL Inc. (SNDL). Click either name above to swap in a different company.
SNDL Inc. is the larger business by last-quarter revenue ($77.5M vs $906.0K, roughly 85.6× Mind Medicine (MindMed) Inc.).
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
SNDL Inc. is a Canada-based consumer goods company focused primarily on the cannabis sector, offering a range of recreational and medical cannabis products, alongside craft beer, wine and spirit offerings. It operates across cultivation, product development, distribution and retail segments, serving both wholesale and retail customers mainly in the North American market.
DFTX vs SNDL — Head-to-Head
Income Statement — Q4 2023 vs Q1 2025
| Metric | | |
|---|---|---|
| Revenue | $906.0K | $77.5M |
| Net Profit | $-23.9M | — |
| Gross Margin | — | 25.3% |
| Operating Margin | -2450.8% | 6.7% |
| Net Margin | -2634.0% | — |
| Revenue YoY | -16.1% | — |
| Net Profit YoY | -386.7% | — |
| EPS (diluted) | $-0.58 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 25 | — | $77.5M | ||
| Q1 24 | — | $116.1M | ||
| Q4 23 | $906.0K | — | ||
| Q3 23 | $1.2M | — | ||
| Q2 23 | $1.3M | — | ||
| Q1 23 | $1.3M | $115.9M | ||
| Q4 22 | $1.1M | — | ||
| Q3 22 | $360.0K | — |
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $-23.9M | — | ||
| Q3 23 | $-17.9M | — | ||
| Q2 23 | $-29.1M | — | ||
| Q1 23 | $-24.8M | — | ||
| Q4 22 | $-4.9M | — | ||
| Q3 22 | $-16.5M | — |
| Q1 25 | — | 25.3% | ||
| Q1 24 | — | 24.8% | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q1 25 | — | 6.7% | ||
| Q1 24 | — | 1.9% | ||
| Q4 23 | -2450.8% | — | ||
| Q3 23 | -1858.6% | — | ||
| Q2 23 | -2226.1% | — | ||
| Q1 23 | -1624.8% | — | ||
| Q4 22 | -1287.0% | — | ||
| Q3 22 | -4717.5% | — |
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | -2634.0% | — | ||
| Q3 23 | -1541.1% | — | ||
| Q2 23 | -2222.0% | — | ||
| Q1 23 | -1932.6% | — | ||
| Q4 22 | -454.0% | — | ||
| Q3 22 | -4579.2% | — |
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $-0.58 | — | ||
| Q3 23 | $-0.45 | — | ||
| Q2 23 | $-0.76 | — | ||
| Q1 23 | $-0.65 | — | ||
| Q4 22 | $-0.02 | — | ||
| Q3 22 | $-0.56 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $99.7M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $78.1M | — |
| Total Assets | $124.5M | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $99.7M | — | ||
| Q3 23 | $117.7M | — | ||
| Q2 23 | $116.9M | — | ||
| Q1 23 | $129.4M | — | ||
| Q4 22 | $142.1M | — | ||
| Q3 22 | $154.5M | — |
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $78.1M | — | ||
| Q3 23 | $96.0M | — | ||
| Q2 23 | $106.0M | — | ||
| Q1 23 | $130.3M | — | ||
| Q4 22 | $150.9M | — | ||
| Q3 22 | $153.6M | — |
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $124.5M | — | ||
| Q3 23 | $141.6M | — | ||
| Q2 23 | $142.1M | — | ||
| Q1 23 | $155.5M | — | ||
| Q4 22 | $170.0M | — | ||
| Q3 22 | $180.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.6M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | $-20.6M | — | ||
| Q3 23 | $-16.6M | — | ||
| Q2 23 | $-13.8M | — | ||
| Q1 23 | $-13.3M | — | ||
| Q4 22 | $-12.8M | — | ||
| Q3 22 | $-9.3M | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
